Clinical Core and Data Coordination Center

丙型肝炎病毒是一个重要的公共卫生问题，其临床结果是可变的。宿主病毒相互作用 在疾病和治疗结果中发挥重要作用，但潜在的免疫机制 导致自发的或治疗相关的病毒清除还不是很清楚。研究 丙型肝炎合作研究中心（HC CRC）的申请重点是 HCV控制的先天免疫机制。所有三个项目中的拟议研究包括 使用慢性丙型肝炎患者的临床标本进行的转化研究，以及体外 本研究旨在评估HCV先天免疫触发、应答和感染控制的机制。 这些研究将依赖于专门的人类肝脏组织、血清、血浆样品和相关的临床试验。 信息.因此，我们建议设立一个临床中心，为这3个项目提供服务 计划，肝脏中心在贝丝以色列女执事医疗中心（BIDMC），哈佛医学院，是一个 在波士顿地区的主要三级转诊中心，并将能够满足临床的要求 核心临床核心将作为U19项目全球研究的中心平台， 提供临床专业知识和充分表征的临床标本，以支持研究 本HC CRC每个单独项目中的假设。

Hepatitis C virus is a significant public health issue and its clinical outcomes are variable. Host virus interactions play important roles in disease and treatment outcomes but the underlying Immunological mechanisms leading to spontaneous or treatment associated viral clearance are not welt understood. The studies proposed within this Hepatitis C Cooperative Research Center (HC CRC) application are focused on the innate immune mechanisms of HCV control. The proposed studies within all three projects Include both translational investigation using clinical specimens from patients with chronic hepatitis C, and in vitro expenments to evaluate mechanisms of HCV innate immune triggering, response, and infection control. These studies will rely on specialized human liver tissues, sera, plasma samples, and the associated clinical Information. Thus, we propose to establish a Clinical Core for service to all three projects in this HC CRC Program, The Liver Center at Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, is a major tertiary referral center in the Boston region and will be able to meet the requirements of the Clinical Core. The Clinical Core will serve as a central platform for the global studies in the U19 Program by providing clinical expertise and well characterized clinical specimens in support of investigating the hypotheses within each individual project of this HC CRC.